retatrutide approval 2025 is the most significant weight-loss pharmaceutical currently in clinical development., Phase 3 TRIUMPH-4 trial results (published December 2025) showed average body weight reduction of When Will Retatrutide Be FDA

Both semaglutide (as Wegovy) and tirzepatide (as Zepbound) are specifically FDA-approved for weight management in people without diabetes who meet BMI criteria

Why Combine CJC-1295 and Ipamorelin

We have identified the parts of the PEPITEM molecule that are responsible for its biological action, and delivered peptides that mimic PEPITEM, and dramatically influence the skin's inflammatory processes

Increasing the number of intestinal endocrine L-cells According to the impairment of L-cells development in T2DM, a promising strategy for treating T2DM is to increase the number of L-cells in the intestine, thereby increasing the production of GLP-1

The development of biomarkers that can reflect the state of ferroptosis in the brain is crucial for enabling early diagnosis, assessing disease progression and monitoring therapeutic responses (Table II)